Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy
-
Published:2023-12-05
Issue:1
Volume:23
Page:
-
ISSN:1471-2407
-
Container-title:BMC Cancer
-
language:en
-
Short-container-title:BMC Cancer
Author:
Zheng Jifang,Zhang Hejun,Li Siya,Kang Zhaoxin,Zheng Fei,Yao Qiwei,Zhang Xueqing,Wu Ziyi,Wang Jiezhong,Fang Weimin,Li Jiancheng,Chen Gang,Chen Yuangui,Chen Mingqiu
Abstract
Abstract
Background
Tumor-infiltrating lymphocytes (TILs) by routine hematoxylin and eosin staining (H&E-TILs) are a robust prognostic biomarker in various cancers. However, the role of H&E-TILs in esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CCRT) has not been reported. The purpose of this study was to assess the prognostic value of H&E-TILs in ESCC treated with CCRT.
Methods
The clinical data of 160 patients with ESCC treated with CCRT in our center between Jan. 2014 and Dec. 2021 were collected and retrospectively reviewed, and propensity score matching (PSM) analyses were performed. The H&E-TILs sections before CCRT were reassessed by two experienced pathologists independently. The H&E-TILs sections were classified into a positive group (+, > 10%) and a negative group (-, ≤ 10%) using 10% as the cutoff. The effects of H&E-TILs on overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) were explored using the Kaplan‒Meier method, and the log-rank test was used to test the differences. Multivariable analysis was performed using the Cox proportion hazards model.
Results
The short-term response to CCRT and the OS (P < 0.001), DMFS (P = 0.001), and LRFS (P < 0.001) rates were significantly different between the H&E-TILs (+) and H&E-TILs (-) groups. Subgroup analysis showed that H&E-TILs(+) with CR + PR group had a longer survival than H&E-TILs(-) with CR + PR, H&E-TILs(+) with SD + PD and H&E-TILs(-) with SD + PD group, respectively(P < 0.001). Furthermore, based on TCGA data, patients in the high TILs group had a better prognosis than those in the low TILs group. Multivariate analyses indicated that H&E-TILs and the short-term response to CCRT were the only two independent factors affecting OS, PFS, DMFS, and LRFS simultaneously, and H&E-TILs expression was associated with an even better prognosis for those patients with CR + PR.
Conclusions
H&E-TILs may be an effective and beneficial prognostic biomarker for ESCC patients treated with CCRT. Patients with H&E-TILs (+) with PR + CR would achieve excellent survival. Further prospective studies are required to validate the conclusions.
Funder
Fujian provincial health and family planning research talent training program the National Natural Science Foundation of China Scientific Research Foundation of Fujian Cancer Hospital Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy National Clinical Key Specialty Construction Program
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference32 articles.
1. Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus Surgery for Esophageal cancer. Cochrane Database Syst Rev. 2017;8(8):Cd010511. 2. Gilbert DC, Serup-Hansen E, Linnemann D, Høgdall E, Bailey C, Summers J, Havsteen H, Thomas GJ. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer. 2016;114(2):134–7. 3. Ruan H, Oike T, Sato H, Ando K, Ohno T. Association between Tumor Mutational Burden, stromal CD8(+) tumor-infiltrating lymphocytes, and clinical factors in cervical cancers treated with Radiotherapy. Cancers. 2023;15(4):1210. 4. Koukourakis IM, Gkegka AG, Xanthopoulou E, Nanos C, Giatromanolaki A, Koukourakis MI. Prognostic and predictive relevance of Tumor-infiltrating lymphocytes in squamous cell Head-Neck Cancer patients treated with Radical Radiotherapy/Chemo-Radiotherapy. Curr Oncol. 2022;29(6):4274–84. 5. Hosch SB, Meyer AJ, Schneider C, Stoecklein N, Prenzel KL, Pantel K, Broelsch CE, Izbicki JR. Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in Esophageal cancer. J Gastrointest Surg. 1997;1(4):316–23.
|
|